NCI disclosure of walk-out by Data and Safety Monitoring Board of the National Lung Screening Trial may be harmful, improper, experts say.
NCI Cancer Bulletin publicized board’s resignation over liability concerns.
NCI reassigns project officer John Gohagan.
Also in this 8-page issue: NCI, FDA open Web site for adverse event reporting.
Kansas Cancer Institute gets $15 million pledge, is renamed, and hires a new director in effort to win NCI center grant.
Funding opportunities listed.
Trending Stories
- Trump administration is removing the mainstays of NCI and the federal government’s cancer program
Peer review, registries, and evidence-based patient information take a big hit - NIH eliminates the NCI Board of Scientific Advisors
Over its 28 year history, BSA shaped NCI-funded extramural science - In the Headlines: “There’s no one to stand up for NCI right now.”
- Bhattacharya cancels NIH all-hands meeting
- An opportunity for Trump: Position U.S. cancer science to lead the world
- Grilled by Congress, Kennedy defends NIH and NCI budget cuts, freezes, and RIFs
To avoid “offending” pharma, NCI doesn’t study the causes of early-onset colon cancer, HHS secretary incorrectly alleges